4-acetoxy-3-ethyl-2-butanone | 1015170-68-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-acetoxy-3-ethyl-2-butanone
• 英文别名: acetic acid 2-ethyl-3-oxo-butyl ester；(2-ethyl-3-oxobutyl) acetate
• CAS: 1015170-68-9
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: DLACXSMYKSOXIH-UHFFFAOYSA-N

物化性质

• 沸点：
  218.2±23.0 °C(Predicted)
• 密度：
  0.979±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-acetoxy-3-ethyl-2-butanone 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 生成 3-亚甲基-2-戊酮
  参考文献：
  名称：

  WO2008/34863

  摘要：

  公开号：
• 作为产物：
  描述：

  carbethoxy-1 ethylene dioxy-2 ethyl-1 propane 在 盐酸 、 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 作用下， 以 乙醚 、 乙醇 、 氯仿 、 水 为溶剂， 反应 4.5h， 生成 4-acetoxy-3-ethyl-2-butanone
  参考文献：
  名称：

  带有环外环的卟啉。第12部分。由环烷基[ b ]吡咯合成内消旋，β-丁酸和中消旋-β-五聚卟啉

  摘要：

  具有b面稠合的七元或八元碳环的吡咯5分别通过与环庚酮或环庚酮的克诺尔缩合反应以高收率制备。在二氯甲烷中用四乙酸铅处理得到不稳定的ω-乙酸酯8，随后酸催化与α-未取代的吡咯-2-羧酸酯的缩合反应，产生了相关的吡咯基环烷基[b]吡咯29和30。α-未取代的吡咯14和23的制备方法是：在DBU存在下，将N，甲苯磺酰基苄基乙酸酯与α，β-未取代的酮或其β-乙酰氧基羰基前体缩合，然后用POCl 3脱水。-吡啶和碱催化消除对甲苯磺酸。将二吡咯二苄基酯29和30在10％Pd-C上氢解，得到相应的二羧酸。在改良的MacDonald“ 2 + 2”条件下，酸与二甲酰基二吡咯基甲烷33的缩合反应得到一系列带有7或8元环外环的四个环烷卟啉4a-d。尽管以良好的产率分离出内消旋的β-丁卟啉4a和4b，但相关的内消旋的β-五杂卟啉4c和4d的结果却较差。。有人提出，八元碳环会扭曲开环四吡咯中间体的几何形状，这种有害影响导致所观察到的较低收率。

  DOI：

  10.1016/s0040-4020(98)00327-5

文献信息

• SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Van Loevezijn Arnold

  公开号：US20080311179A1

  公开（公告）日：2008-12-18

  This invention concerns compounds of the general formula (1). and derivatives thereof, which are antagonists of 5-HT 6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

  本发明涉及通式（1）的化合物及其衍生物，它们是5-HT6受体拮抗剂，其中符号的含义如说明书所示。本发明还涉及制备这些化合物的方法，对于其合成有用的新型中间体，以及这些化合物和组合物的用途，特别是将它们用于向患者施用以达到治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓损伤或头部损伤有关的疾病、脑积水、功能性肠道障碍、肠易激综合征、肥胖症和2型糖尿病等至少一种疾病或症状的治疗效果。
• Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists
  申请人：Solvay Pharmaceuticals B.V.

  公开号：US07728018B2

  公开（公告）日：2010-06-01

  This invention concerns compounds of the general formula (1): and derivatives thereof, which are antagonists of 5-HT6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

  这项发明涉及一般式（1）的化合物及其衍生物，它们是5-HT6受体的拮抗剂，其中符号具有描述中所给出的含义。该发明还涉及制备这些化合物的方法，对于其合成有用的新中间体，以及这些化合物和组合物的用途，特别是将它们用于给患者治疗至少一种疾病或病状，包括帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安躁动、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓损伤或头部损伤相关的疾病、脑积水、功能性肠道紊乱、肠易激综合征、肥胖症和2型糖尿病。
• SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP2069310A2

  公开（公告）日：2009-06-17
• SULFONYLPYRAZOLINE-1-CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Abbott Healthcare Products B.V.

  公开号：EP2069310B1

  公开（公告）日：2011-12-14
• Ghrelin Mimetic Polypeptide Hapten Immunoconjugates Having Improved Solubility and Immunogenicity and Methods of Use Thereof
  申请人：Janda Kim D.

  公开号：US20140086949A1

  公开（公告）日：2014-03-27

  Immunoconjugates for impeding weight gain and treating obesity in a subject are disclosed. The immunoconjugates comprise a ghrelin mimetic polypeptide hapten, a spacer moiety comprising one of more polyethylene glycol (PEG) units, and a protein carrier moiety. Immunoconjugates optionally include a conjugation moiety for conjugating the polypeptide hapten with a linker moiety or the protein carrier moiety and a linker moiety for conjugating the conjugation moiety with the protein carrier moiety.